Loading
CDKN1B (Cyclin-dependent kinase inhibitor 1B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer, Prostate cancer, Breast cancer and 5 more.
Important regulator of cell cycle progression. Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA. Involved in G1 arrest.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Lapatinib, Cisplatin and Fluorouracil. Open Targets scores its association with cancer at 0.81 (direct and indirect evidence; datatypes genetic literature 0.73, affected pathway 0.76, literature 0.99, genetic association 0.75, somatic mutation 0.90, animal model 0.54). IntOGen calls it a driver in 12 cohorts (1 activating, 11 loss-of-function), covering Invasive Breast Carcinoma, Hepatocellular Carcinoma, Plasma Cell Myeloma, Prostate Adenocarcinoma, Small Intestinal Carcinoma.
In plain words · CDKN1B (Cyclin-dependent kinase inhibitor 1B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer, Prostate cancer, Breast cancer and 5 more.
CDKN1B (Cyclin-dependent kinase inhibitor 1B) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Thyroid cancer, Prostate cancer, Breast cancer and 5 more.
Important regulator of cell cycle progression. Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA.
No product in this corpus aims at CDKN1B yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA CDKN1B: RNA low tissue specificity; high antibody staining in 9 normal tissues; highest cancer staining carcinoid (1 of 4 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Thyroid cancer, Prostate cancer, Breast cancer (all types), Neuroendocrine tumours, Head and neck squamous cell carcinoma, Multiple myeloma, Hepatocellular carcinoma and more); Open Targets associates it with 6 specific cancer types at or above 0.5 (multiple endocrine neoplasia type 4, prostate carcinoma, hereditary neoplastic syndrome, thyroid gland carcinoma, pituitary gland adenoma, thyroid cancer). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P46527; CIViC gene CDKN1B; IntOGen CDKN1B; Human Protein Atlas CDKN1B tissue; Open Targets ENSG00000111276 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Polyak et al, Cell, 1994, "Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals". Source.
Sources: HGNC HGNC:1785 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P46527 (protein name, function text, keywords and locations (REST API)); CIViC gene CDKN1B (2 evidence items, 0 assertions, 2 variants; diseases: Breast Cancer, Head And Neck Squamous Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000111276 (association with cancer (MONDO_0004992) 0.81; per-cancer scores at or above 0.5: prostate cancer 0.63, thyroid cancer 0.65, neuroendocrine neoplasm 0.62, acute lymphoblastic leukaemia 0.53, non-Hodgkin lymphoma 0.56, breast cancer 0.63 (GraphQL API, CC0)); IntOGen CDKN1B (driver in 12 cohorts (Act 1, LoF 11); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Important regulator of cell cycle progression. Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichiometry. Location: Nucleus; Cytoplasm; Endosome (UniProt). Locus 12p13.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adrenal gland, Appendix, Cerebral cortex, Colon, Endometrium, Gallbladder, Liver, Lymph node.
Medium only: cervical cancer, colorectal cancer, head and neck cancer, liver cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | 1-4% | Deep deletion | cBioPortal deep deletion: 20 of 489, 4.1%, in prad_tcga_pan_can_atlas_2018; 22 of 1,013, 2.2%, in prad_p1000; 13 of 424, 3.1%, in prad_mcspc_mskcc_2020; 71 of 2,260, 3.1%, in prostate_msk_2024; 52 of 1,465, 3.5%, in prad_cdk12_mskcc_2020; 13 of 444, 2.9%, in prad_su2c_2019. | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"CDKN1B" OR ABSTRACT:"CDKN1B" OR TITLE:"cyclin dependent kinase inhibitor 1B" OR ABSTRACT:"cyclin dependent kinase inhibitor 1B" OR TITLE:"Cyclin-dependent kinase inhibitor 1B" OR ABSTRACT:"Cyclin-dependent kinase inhibitor 1B" OR TITLE:"KIP1" OR ABSTRACT:"KIP1" OR TITLE:"P27KIP1" OR ABSTRACT:"P27KIP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CDKN1B, not a curated reading list.
Shares Thyroid cancer, Hepatocellular carcinoma, IntOGen, Multiple myeloma.
Shares Thyroid cancer, Neuroendocrine tumours, CIViC, Open Targets Platform.
Shares Thyroid cancer, Neuroendocrine tumours, CIViC, IntOGen.
Shares Thyroid cancer, Neuroendocrine tumours, Hepatocellular carcinoma, IntOGen.
Shares Thyroid cancer, Neuroendocrine tumours, IntOGen, Head and neck squamous cell carcinoma.
Shares Small intestine cancer (small bowel adenocarcinoma), Neuroendocrine tumours, IntOGen, Multiple myeloma.
Shares Thyroid cancer, Neuroendocrine tumours, IntOGen, Breast cancer (all types).
Shares Thyroid cancer, Neuroendocrine tumours, CIViC, Open Targets Platform.